Related references
Note: Only part of the references are listed.Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients
Zhe Yang et al.
CLINICAL CANCER RESEARCH (2018)
Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA
Travis A. Clark et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2018)
Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance
Zhen Wang et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer
Surein Arulananda et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib
Sai-Hong Ignatius Ou et al.
LUNG CANCER (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
Matthew J. Niederst et al.
CLINICAL CANCER RESEARCH (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
Zofia Piotrowska et al.
CANCER DISCOVERY (2015)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
